Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status-Reference-Cited by-同舟云学术

Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status

Published:2012-07 Issue:11 Volume:48 Page:1739-1749
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Eisenhofer Graeme,Lenders Jacques W.M.,Siegert Gabriele,Bornstein Stefan R.,Friberg Peter,Milosevic Dragana,Mannelli Massimo,Linehan W. Marston,Adams Karen,Timmers Henri J.,Pacak Karel

Funder

European Union 7th Framework Program

Deutsche Forschungsgesellschaft

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Malignant pheochromocytoma: current status and initiatives for future progress;Eisenhofer;Endocr Relat Cancer,2004

2. The diagnosis and management of malignant phaeochromocytoma and paraganglioma;Chrisoulidou;Endocr Relat Cancer,2007

3. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma;Brouwers;Endocr Relat Cancer,2005

4. Gene expression profiling of benign and malignant pheochromocytoma;Brouwers;Ann NY Acad Sci,2006

5. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis;Strong;Surgery,2008

Cited by 304 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice;Molecular and Cellular Endocrinology;2024-10

2. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial;European Journal of Cancer;2024-09

3. Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients;Best Practice & Research Clinical Endocrinology & Metabolism;2024-09

4. Management of Pheochromocytomas and Paragangliomas;Surgical Clinics of North America;2024-08

5. MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma;Best Practice & Research Clinical Endocrinology & Metabolism;2024-08